BioSpace News Archive

ANI Pharmaceuticals, Inc. announced that the Company will release its third quarter 2023 financial results on Wednesday, November 8, 2023, prior to the market open.

Groupe LSL Pharma Inc. announces that its subsidiary LSL Laboratory has received new orders for natural health products.

BioXcel Therapeutics, Inc. today announced positive findings from an independent third party audit of the data from a single site1 in its TRANQUILITY II Phase 3 trial.

Diadem SpA, (Diadem), a company developing one of the first blood-based tests for the early and accurate prediction of clinical progression to Alzheimer’s disease (AD), today announced that it has formed a strategic collaboration with Quest Diagnostics.

Medicenna Therapeutics Corp. today announced dosing of the first patient in the Phase 2 monotherapy dose expansion portion of the Phase 1/2 ABILITY (ABeta-only IL-2 ImmunoTherapY) study evaluating MDNA11, a long-acting, beta-only interleukin-2 (IL-2) super-agonist.

Inspira™ Technologies OXY BHN Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira "), a company dedicated to advancing acute respiratory care by enabling breathing without lungs, announced today the grant of an additional patent by the U.S. Patent and Trademark Office for its respiratory medical device, the INSPIRATM ART500.

Akebia Therapeutics today announced the U.S. Food and Drug Administration (FDA) has acknowledged that the resubmission to its New Drug Application (NDA) for vadadustat as a treatment for anemia due to chronic kidney disease (CKD) in adult patients on dialysis, was complete.

Evolus, Inc. today announced that it will report its third quarter 2023 financial results and provide a business update on Tuesday, November 7, 2023, after the U.S. financial markets close.

Bio-Techne Corporation (NASDAQ: TECH) today announced that Lunaphore, a Bio-Techne brand, will have its technologies featured in several presentations by prominent research centers at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, taking place in San Diego, November 1-5, 2023.

Theranica, a neuromodulation therapeutics company, announced the publication of a comprehensive clinical study in Advances in Therapy examining the long-term utilization, clinical efficacy, and safety of Nerivio®, a Remote Electrical Neuromodulation (REN) device for the treatment of migraine.